FAB122 (Daily Oral Edaravone)

edaravone · Ferrer Internacional S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FAB122 (Daily Oral Edaravone), covering 2025-03-18 to 2025-03-18. Get the full timeline:

Most recent: Clinical Trial Update: Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis [Phase 3]

See pricing